Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors Sophie Feng, M.B.B.S., Jermaine Coward, PhD,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma Dean A. Fennell, PhD, FRCP,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer Eiko Theodora Browning, MD, Andrew James.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Frank Detterbeck, MD Journal of Thoracic Oncology

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Prevention and Management of Bone Metastases in Lung Cancer: A Review

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

George Blumenschein, MD, John V. Heymach, MD, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

A Lung Cancer Responding to Hormonal Therapy

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

A Primer on Health Economic Evaluations in Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective.

It’s All in the “Swerve of the Curve”

Pulmonary Metastasectomy in Breast Cancer

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

M. Kusumoto Journal of Thoracic Oncology

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

S-1 Treatment for Chemorefractory Thymic Carcinoma

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

David Garfield, MD Journal of Thoracic Oncology

Regression of Paraneoplastic Rash after Lung Cancer Chemotherapy

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Haval Balata, MBChB, MRCP, Kwun M. Fong, M. B. B. S

Presentation transcript:

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors Sophie Feng, M.B.B.S., Jermaine Coward, PhD, Elizabeth McCaffrey, M.B.B.S., John Coucher, M.B.B.S., Paul Kalokerinos, M.B.B.S., Ken O’Byrne, MD Journal of Thoracic Oncology Volume 12, Issue 11, Pages 1626-1635 (November 2017) DOI: 10.1016/j.jtho.2017.08.007 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Progress scans before commencement and after cessation of pembrolizumab. Journal of Thoracic Oncology 2017 12, 1626-1635DOI: (10.1016/j.jtho.2017.08.007) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions